Top ranked tumor entities, such as ovarian carcinomas, endometrium carcinomas, pancreatic adenocarcinomas, and malignant mesothelioma, thus, may be the best candidates for therapy with drugs targeting MSLN. The gene discussed is MSLN; the disease is neoplasm.